Stay updated with breaking news from Reduced Intensity Conditioning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Doctors and scientists with City of Hope, one of the largest cancer research and treatment organizations in the United States, presented data...
/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that an abstract...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-1801, a potentially curative lentiviral gene therapy for sickle cell disease (SCD), will be delivered in an oral presentation at the 15th Annual Sickle Cell Disease Research & Educational Symposium & 44th National Sickle Cell Disease Scientific Meeting. Dr. Monika Asnani, professor of family medicine & epidemiology at the Caribbean Institute for Health Research, will present data from the ARU-1801 Phase 1/2 MOMENTUM clinical trial dur...
Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States February 02, 2021 14:21 ET | Source: Medexus Pharmaceuticals Inc Medexus Pharmaceuticals Inc Orphan Designated Drug with August 2021 PDUFA date Management to host conference call at 10:00 AM Eastern Time on February 3, 2021 and Key Opinion Leader webinar to be held at 2:00 PM Eastern Time on February 5, 2021 TORONTO and CHICAGO and MONTREAL and WEDEL, Germany, Feb. 02, 2021 (GLOBE NE...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class ... Medexus Pharmaceuticals IncFebruary 2, 2021 GMT Orphan Designated Drug with August 2021 PDUFA date Management to host conference call at 10:00 AM Eastern Time on February 3, 2021 and Key Opinion Leader webinar to be held at 2:00 PM Eastern Time on February 5, 2021 TORONTO and CHICAGO and MONTREAL and WEDEL, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus”) (TSXV: MDP) (O...